Today: 28 June 2026
Browse Category

Biotechnology 24 October 2025 - 4 November 2025

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis reported 2024 revenue of $9.3 billion, up 9% from 2023, with gross margins near 72% and net profit margin around 29%. Shares traded at $130–$135 in November 2025, down from a 52-week high of $180. The company raised its dividend by 15% to $2.00 per share. Analysts’ average 12-month target is $188, though some issued downgrades in late 2025 amid slowing growth.
4 November 2025
··
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

Sarepta Therapeutics shares plunged nearly 80% in 2025, falling from a high of $138.81 to around $15 after its Phase 3 ESSENCE trial failed and the FDA halted gene therapy trials following patient deaths. Q3 revenue beat estimates at $399.4 million, but the company posted a $179.9 million net loss. Sarepta restricted Elevidys sales to ambulatory patients after the FDA intervention. Analyst consensus is Hold, with a $34.50 average price target.
4 November 2025
··
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals’ shares surged over 100% on November 3 after announcing positive Phase 1b results for its PH-762 skin cancer therapy, with one patient achieving full tumor clearance. No serious adverse effects were reported at any dose. The company, with a $12 million pre-rally market cap and no revenue, holds enough cash to fund operations into 2026 but will need more capital for larger trials. Analyst outlooks remain mixed.
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 November 2025
··
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou Biosciences reported its off-the-shelf CAR-T therapy vispa-cel achieved a 64% complete remission rate in lymphoma, with 51% of patients cancer-free after one year. In multiple myeloma, CB-011 showed a 92% overall response rate. Shares of Caribou more than doubled after the Nov. 3 announcement. No graft-vs-host disease was observed, though one fatal toxicity occurred.
3 November 2025
··
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta Bio shares surged up to 46% on Oct. 31, closing at $3.61 after strong CAR-T therapy data, with trading volume hitting 35.7 million shares. Phase 1/2 results showed major improvements in myositis and systemic sclerosis, and durable lupus nephritis remissions. The company remains pre-revenue, holding $194.7 million cash as of June 30. Wall Street analysts mostly rate CABA a “Buy,” with targets averaging $13–15.
31 October 2025
··
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··
Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience shares fell to $0.40 in October 2025, down 84% year-over-year, after hitting a 52-week low of $0.28. Nasdaq granted a 180-day extension to regain $1 compliance, and the company is considering a reverse split. Q2 revenue dropped 12% to $20.5 million, but cash flow improved. Debt refinancing is required by December 2025, and John Duke became CEO in July after Jim Green’s retirement.
30 October 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Therapeutics shares plunged nearly 45% on Oct. 27 after the company halted two Phase 3 trials of its CRISPR therapy due to a patient suffering severe liver toxicity. The stock dropped from the mid-$20s to the low-teens, with NTLA trading around $14–15 as of midday Oct. 28. Several analysts downgraded the stock and cut price targets following the safety incident.
28 October 2025
···
Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics (CODX) Stock Skyrockets 200% on Saudi JV – Is This Just the Beginning?

Co-Diagnostics shares jumped over 200% to close at $1.07 on October 27 after announcing a joint venture with Arabian Eagle Manufacturing to distribute PCR tests across the Middle East and North Africa. Trading volume topped 100 million shares amid a surge in retail investor activity. The company recently reported Q2 revenue of $200,000, down sharply from the prior year. Analyst price targets ranged from $1.00 to $3.00.
27 October 2025
··
Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

Intellia Therapeutics shares plunged nearly 45% Monday after the company halted two Phase 3 trials of its CRISPR therapy NTLA-2001 due to a severe liver injury in a patient. The stock dropped from about $19 to the low teens, with CRISPR Therapeutics also falling 10%. Intellia paused dosing and enrollment following the Grade 4 liver event and is consulting regulators on next steps.
27 October 2025
···
CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

CRISPR Therapeutics traded near $67 on Oct. 27, down 3% after safety concerns hit gene-editing stocks. Shares remain up nearly 100% in 2025, fueled by a major preclinical breakthrough and global rollout of its Casgevy therapy. Rival Intellia plunged 45% after a trial pause, dragging CRSP down 10% in sympathy. Analysts remain bullish, with targets up to $93 despite sector volatility.
27 October 2025
··
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion (RXRX) Stock Surges on AI Drug Discovery Hype – What’s Driving the Rally?

Recursion Pharmaceuticals closed at $6.04 on Oct. 24, 2025, after volatile trading and a 44% monthly surge. Q2 revenue rose 33% to $19.2 million, but net loss reached $171.9 million as R&D spending climbed. The company completed a $630 million merger with Exscientia and reported $534 million cash on hand. Key drug candidates advanced in clinical trials, with several late-stage readouts expected by year-end.
26 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··
1 … 13 14 15 16 17 … 19

Stock Market Today

  • M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons
    June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100's top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company's strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from peers like Aviva and Legal & General, M&G's solid execution and brand strength underpin confidence in ongoing dividend growth. Investors are advised to consider these factors carefully before buying shares.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 5:49 AM EDT M&G Emerges as a Leading FTSE 100 Dividend Stock: Five Key Reasons June 28, 2026, 5:41 AM EDT. M&G (LSE:MNG) has become one of the FTSE 100’s top dividend stocks since its 2019 spin-off from Prudential, with annual dividend increases reflecting resilience and robust cash flows. Its dividend yield has averaged 6.3%, significantly outpacing the FTSE 100 average of 3-4%. The company’s strong Solvency II capital ratio and a conservative cash-flow-to-payout ratio of 63% support a progressive and sustainable dividend policy. Despite competitive pressures from
Go toTop